Disc Medicine (IRON)
NASDAQ:IRON
Want to see IRON full AI Analyst Report?
IRON Stock Chart & Stats
$69.45
$0.74(1.19%)
At close: 4:00 PM EST
$69.45
$0.74(1.19%)
Day’s Range― - ―
52-Week Range$40.00 - $99.50
Previous CloseN/A
Volume41.94K
Average Volume (3M)529.34K
Market Cap
$2.68B
Enterprise Value$2.56B
Total Cash (Recent Filing)$791.15M
Total Debt (Recent Filing)$1.86M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
May 07, 2026EPS Estimate
-1.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding38,160,065
10 Day Avg. Volume395,868
30 Day Avg. Volume529,339
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-15.46
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.55K
Enterprise Value/Ebitda-12.37
Forecast
1Y Price Target
$97.67Price Target Upside40.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-6.89
Revenue Forecast (FY)$6.08M
Bulls Say, Bears Say
Bulls Say
APOLLO Trial ReadoutAPOLLO trial results could show meaningful reductions in porphyrin buildup and improved sunlight tolerance for bitopertin, supporting a traditional approval resubmission.
Balance Sheet StrengthA strong cash position that does not assume bitopertin revenues supports funding of ongoing programs through key readouts, reducing near-term financing risk.
Pipeline Clinical DataTopline readouts from DISC-0974 and DISC-3405 could de-risk the portfolio by demonstrating efficacy in anemia indications and robust hepcidin induction, expanding confidence in the company's therapeutic approach.
Bears Say
Biomarker UncertaintyRegulator concerns that reductions in PPIX may not reliably predict clinical benefit create uncertainty about acceptable endpoints and could necessitate additional confirmatory evidence.
Regulatory SetbackThe FDA's complete response letter for bitopertin represents a regulatory setback that delays approval and requires a refined strategy for resubmission.
Restructuring And WorkforcePlanned workforce reductions and restructuring signal operational disruption and are likely to generate one-time charges that pressure near-term financial results.
Disc Medicine News
IRON FAQ
What was Disc Medicine’s price range in the past 12 months?
Disc Medicine lowest stock price was $40.00 and its highest was $99.50 in the past 12 months.
What is Disc Medicine’s market cap?
Disc Medicine’s market cap is $2.68B.
When is Disc Medicine’s upcoming earnings report date?
Disc Medicine’s upcoming earnings report date is May 07, 2026 which is in 19 days.
How were Disc Medicine’s earnings last quarter?
Disc Medicine released its earnings results on Feb 26, 2026. The company reported -$1.64 earnings per share for the quarter, beating the consensus estimate of -$1.71 by $0.07.
Is Disc Medicine overvalued?
According to Wall Street analysts Disc Medicine’s price is currently Undervalued.
Does Disc Medicine pay dividends?
Disc Medicine does not currently pay dividends.
What is Disc Medicine’s EPS estimate?
Disc Medicine’s EPS estimate is -1.65.
How many shares outstanding does Disc Medicine have?
Disc Medicine has 38,160,065 shares outstanding.
What happened to Disc Medicine’s price movement after its last earnings report?
Disc Medicine reported an EPS of -$1.64 in its last earnings report, beating expectations of -$1.71. Following the earnings report the stock price went up 1.525%.
Which hedge fund is a major shareholder of Disc Medicine?
Currently, no hedge funds are holding shares in IRON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Disc Medicine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$97.67 (40.63% Upside)
$97.67 (40.63% Upside)
Blogger Sentiment
Bullish
IRON Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 532.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
69.88%
12-Months-Change
Fundamentals
Return on Equity
-32.80%
Trailing 12-Months
Asset Growth
62.42%
Trailing 12-Months
Company Description
Disc Medicine
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
IRON Stock 12 Month Forecast
Average Price Target
$97.67
▲(40.63% Upside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Arcutis Biotherapeutics
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
9.36% Insiders
27.85% Mutual Funds
0.04% Other Institutional Investors
50.90% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---